Anixa Biosciences, Inc. (ANIX)
$2.98
Insights on Anixa Biosciences, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 82.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 278.2%
Performance
- $2.94$3.32$2.98
1.34%
Downside
Day's Volatility :11.45%
Upside
10.24%
- $2.75$5.13$2.98
7.72%
Downside
52 Weeks Volatility :46.39%
Upside
41.91%
Returns
| Period | Anixa Biosciences, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -31.96% | 0.5% | 0.0% |
6 Months | -5.4% | 11.7% | 0.0% |
1 Year | -29.88% | 6.2% | 2.2% |
3 Years | -38.68% | 13.5% | -23.0% |
Highlights
Market Capitalization | 101.4M |
Book Value | $0.78 |
Earnings Per Share (EPS) | -0.34 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -5744.76% |
Return On Assets TTM | -28.09% |
Return On Equity TTM | -43.02% |
Revenue TTM | 210.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 127.5K |
EBITDA | -13.1M |
Diluted Eps TTM | -0.34 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.44 |
EPS Estimate Next Year | -0.45 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 302.68%
Technicals Summary
Sell
Neutral
Buy
Anixa Biosciences, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Anixa Biosciences, Inc. | -4.79% | -5.4% | -29.88% | -38.68% | -29.05% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Anixa Biosciences, Inc. | NA | NA | NA | -0.44 | -0.43 | -0.28 | NA | 0.78 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Anixa Biosciences, Inc. | Buy | $101.4M | -29.05% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
Vanguard Group Inc
4.37%UBS Group AG
1.82%Mission Wealth Management, LLC
1.57%Laird Norton Tyee Trust Co
1.16%Geode Capital Management, LLC
0.98%Long Focus Capital Management, LLC
0.52%
Corporate Announcements
Anixa Biosciences, Inc. Earnings
Anixa Biosciences, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues
Organization | Anixa Biosciences, Inc. |
Employees | 4 |
CEO | Dr. Amit Kumar Ph.D. |
Industry | Electronic Technology |
